Shopping Cart
- Remove All
- Your shopping cart is currently empty
TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 mg | Inquiry | Backorder | |
500 mg | Inquiry | Backorder |
Description | TT-OAD2 free base has the potential for diabetes treatment. TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. |
Targets&IC50 | GLP1 receptor:(EC50)5 nM |
In vitro | TT-OAD2, at concentrations ranging from 0 to 10 μM, suppresses GLP-1- and oxyntomodulin-induced responses—including cAMP, calcium, pERK1/2, and β-arrestin—in a dose-dependent manner within HEK293A cells. |
In vivo | TT-OAD2 ?treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice. |
Molecular Weight | 856.83 |
Formula | C50H47Cl2N3O6 |
Cas No. | 1246826-07-2 |
Relative Density. | 1.31g/cm3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.